Medicare Deal Broadens Access to TONMYA Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has signed a new managed Medicare payer agreement for its fibromyalgia treatment TONMYA® (cyclobenzaprine HCl ...

New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the ...

Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https://ir.tonixpharma.com/. Tonix ...

HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl ...

Central Nervous System (CNS) PipelineTNX-102 SL (cyclobenzaprine HCl sublingual tablets 2.8 mg): two tablets (5.6 mg), once-daily at bedtime for fibromyalgia (FM) – a centrally-acting, non-opioid ...

Tonix Pharmaceuticals (TNXP) stock and MapLight Therapeutics (MPLT) stock gains as Raymond James issues them new Strong Buy ratings. Read more here.

Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) shares have nearly doubled over the past month despite the pullback on Wednesday. Here’s what you need to know. What To Know: Tonix shares traded higher in ...

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) stands against other stocks ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are moving higher on Friday after the company provided preliminary 2024 fiscal-year financial results. What To Know: The company reported net ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...